Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Tanabe completes Choseido acquisition

This article was originally published in Scrip

Executive Summary

Mitsubishi Tanabe Pharmaceutical(MTP) has completed its acquisition of the small Japanese generics firm Choseido Pharmaceutical. MTP raised its ownership of the firm from 10% to 51% through the purchase of 697,000 shares, in a deal first announced earlier this year (Scrip Online, May 8th, 2008). The price was not disclosed but MTP said the impact on its results would be minor. Choseido had sales of ¥5.6 billion ($51.4 million) in the last fiscal year, and will manufacture products for sale through MTP's new generics marketing operation, Tanabe Seiyaku Hanbai.

You may also be interested in...



Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types

RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.

Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma

Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.

Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem

The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?

Topics

UsernamePublicRestriction

Register

SC001552

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel